It’s daggers out at the Federal Trade Commission in its fight against anticompetitive practices in health care. This past year, it has issued more stringent guidelines to block and discourage hospital mergers, and it investigated practices by middlemen in the drug supply chain. Now drug manufacturers themselves are in the agency’s crosshairs. In November, the FTC challenged the validity of more than 100 drug patents in the Food and Drug Administration’s “Orange Book.” It’s a novel attack on drug prices. The Orange Book is where drug companies list patents, which they argue protect their products from competition. Generic drugmakers seeking to make a copycat version of
Hence then, the article about the ftc escalates biden s fight against drug prices was published today ( ) and is available onKHN ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details Finally We wish PressBee provided you with enough information of ( The FTC Escalates Biden’s Fight Against Drug Prices )